lenalidomide has been researched along with methylprednisolone in 9 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (methylprednisolone) | Trials (methylprednisolone) | Recent Studies (post-2010) (methylprednisolone) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 20,247 | 2,602 | 5,317 |
| Protein | Taxonomy | lenalidomide (IC50) | methylprednisolone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.011 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.011 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.011 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.011 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Erdel, M; Fiegl, M; Kilga-Nogler, S; Köck, L; Schennach, H; Sun, WL; Walder, A | 1 |
| Suzuki, K | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Aoyama, K; Arakawa, F; Morishige, S; Mouri, F; Nagafuji, K; Nakamura, T; Nishi, M; Ohshima, K; Osaki, K; Oya, S; Saruta, H; Seki, R; Yamaguchi, M; Yamasaki, Y | 1 |
| Berenson, JR; Ghermezi, M; Spektor, TM | 1 |
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Berenson, JR; Bujarski, S; Eades, BR; Emamy-Sadr, M; Green, T; Souther, E; Spektor, TM; Sutanto, C; Swift, RA; To, J | 1 |
3 review(s) available for lenalidomide and methylprednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
The role of JAK inhibitors in multiple myeloma.
Topics: Dexamethasone; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Methylprednisolone; Multiple Myeloma; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
1 trial(s) available for lenalidomide and methylprednisolone
| Article | Year |
|---|---|
Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Dexamethasone; Humans; Lenalidomide; Methylprednisolone; Multiple Myeloma; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines | 2022 |
5 other study(ies) available for lenalidomide and methylprednisolone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immunoglobulins; Lenalidomide; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.
Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Pulse Therapy, Drug; Recurrence; Stevens-Johnson Syndrome; Transplantation, Haploidentical; Treatment Outcome | 2019 |
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |